Jun. 17 at 5:47 PM
$SAGE surges 35.4% on acquisition news! 🚀
Supernus Pharmaceuticals is set to acquire Sage Therapeutics at
$8.50/share, with a potential total value of
$12/share if sales milestones are hit through a contingent value right. This acquisition will grant
$SUPN rights to SAGE’s new depression drug, Zurzuvae, boosting its diverse neuroscience portfolio.
Discover the full deal details here 👉 https://www.zacks.com/commentary/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-body&ADID=SYND_STOCKTWITS_TWEET_2_2507455_BODY